Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: A case series

Journal of Dermatology

Volumn 38, Issue 11, 2011, Pages 1096-1099

  Wang, Ting Shun ^a   Tsai, Tsen Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; EFALIZUMAB; EMOLLIENT AGENT; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

ADULT; BODY SURFACE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; ERYTHRODERMIC PSORIASIS; EXPERIENCE; FEMALE; FOLLOW UP; HUMAN; LETTER; MALE; PSORIASIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ASIAN CONTINENTAL ANCESTRY GROUP; DERMATITIS, EXFOLIATIVE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; TAIWAN; TIME FACTORS;

EID: 80355133443     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2011.01224.x     Document Type: Letter

References (10)

1. Yeh MH, Tsai TF,. Clinical analysis of psoriatic inpatients-A 10-year retrospective study. Dermatol Sinica 2007; 25 (2): 103-111.
2. Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S,. Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol 2006 Jul; 155 (1): 156-159. (Pubitemid 43876409)
3. Takahashi MD, Castro LG, Romiti R,. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol 2007 Oct; 157 (4): 828-831. (Pubitemid 47389895)
4. Poulalhon N, Begon E, Lebbé C, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol 2007 Feb; 156 (2): 329-336. (Pubitemid 46095962)
5. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008 May 31; 371 (9625): 1665-1674. (Pubitemid 351671883)
6. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008 May 17; 371 (9625): 1675-1684. (Pubitemid 351671884)
7. Youn JL, Tsai TF, Song M, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: results of a phase 3 trial in Taiwanese and Korean patients. The First Eastern Asian Dermatology Congress (EADC2010).
8. Santos-Juanes J, Coto-Segura P, Mas-Vidal A, Galache Osuna C,. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies. Br J Dermatol 2010 May; 162 (5): 1144-1146.
9. Gulliver WP,. HLA-Cw6 and TNF-alpha polymorphism may help predict response to biologic therapy in patients with chronic plaque psoriasis. Canadian Dermatology Association 82th Annual Conference, Toronto, Ontario 2007.
10. Costanzo A, Talamonti M, Mazzotta A, Papoutsaki M, Chimenti S,. HLA-Cw6 allele confers sensitivity to Efalizumab treatment in psoriasis. Psoriasis. From Gene to Clinic, 5th International Congress. London, U.K., December 4-6, 2008.